ISO 10993-3:2026 Published: What Medical-Device Teams Should Review Now

What ISO Publicly Confirms

The official ISO catalogue page for ISO 10993-3:2026 identifies the publication as Edition 4, dated August 2026, with 41 pages. ISO states that it replaces both ISO 10993-3:2014 and ISO/TR 10993-33:2015.

The public scope describes evaluation of genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity for medical devices. It applies after the need to evaluate one or more of those biological effects has been established under ISO 10993-1. It does not itself make every endpoint applicable to every device.

The public scope also excludes regulated active pharmaceutical ingredients in device–drug combination products and biological components in device–biologic combination products from this document's coverage. Product-specific combination-product requirements therefore need their own route analysis.

High-Level Changes Identified in the Official Foreword

ISO's public preview provides the foreword and table of contents, but not the operative clauses or annex text. At that public level, the foreword identifies these principal changes from the previous edition:

• Testing to evaluation: the revision shifts its overall emphasis from tests alone toward evaluation of the four biological effects.
• Chemistry and toxicology: chemical characterization and toxicological risk assessment are added as an approach within the evaluation of those effects.
• Genotoxicity follow-up: the approach after a positive in-vitro genotoxicity result changes, and the former flowchart is removed.
• Separate reproductive and developmental treatment: reproductive toxicity and developmental toxicity are described separately.
• Annex changes: the cellular-transformation annex is deleted, while content from ISO/TR 10993-33 is incorporated into a genotoxicity-test annex.

These points are suitable for scoping an impact review. They are not enough to reconstruct the detailed requirements, acceptance logic, decision criteria or annex procedures that remain inside the licensed standard.

What Teams Can Assess Now

• Controlled standards register: identify every BEP, BER, risk-management record, protocol, report, procedure and template that cites ISO 10993-3:2014 or ISO/TR 10993-33:2015.
• Endpoint applicability: confirm that the need to evaluate genotoxicity, carcinogenicity, reproductive toxicity or developmental toxicity is established through the current ISO 10993-1 risk-based process rather than copied from a generic table.
• Evidence route: map existing chemical characterization, toxicological assessment, literature, test data, clinical information and device-specific exposure assumptions to each applicable Part 3 effect.
• Genotoxicity follow-up: flag files that rely on the former positive-in-vitro follow-up flowchart or unexplained legacy sequencing.
• Reproductive and developmental conclusions: locate combined conclusions that may need to be separated when the licensed text is available.
• Legacy TR 33 references: identify procedures or reports that treat ISO/TR 10993-33 as a separate current source and plan a controlled cross-reference review.
• Change-control decision: record whether the effect is editorial, procedural, evidence-related or potentially substantive; assign an owner and a hold point before any testing decision.
• Market route: keep ISO publication status separate from FDA recognition, EU harmonisation and India adoption status.

What Not to Infer From Publication

• No automatic retesting: publication does not make existing evidence invalid or require every legacy device to repeat testing.
• No automatic chemistry-only conclusion: adding chemical characterization and TRA as an approach does not mean chemistry replaces all biological evidence or testing in every case.
• No universal endpoint list: Part 3 applies after endpoint need is established; it is not a reason to select all four effects for every device.
• No automatic regulator acceptance: an ISO publication is not the same as FDA recognition, EU harmonisation or BIS adoption.
• No clause reconstruction: the public foreword and contents cannot support detailed claims about operative requirements or methods.

Regulatory Status Checked August 23, 2026

A Practical, No-Regret Transition Sequence

1. Record the publication event in the standards and regulatory-intelligence register.
2. Run a document search for ISO 10993-3:2014, ISO/TR 10993-33:2015, the former genotoxicity flowchart and combined reproductive/developmental conclusions.
3. Classify each impact as reference-only, process, evidence-evaluation, or possible testing-strategy impact.
4. Separate market status so the file does not call the 2026 edition FDA-recognized, EU-harmonized or BIS-adopted without a current official basis.
5. Delay irreversible decisions such as new testing until the licensed clauses, device facts and target-authority context have been reviewed together.
6. Update controlled outputs once through change control, with the rationale, affected documents, review date and approver visible.

Revision Record and Next Review Triggers

Current page version: Public-source transition assessment, reviewed August 23, 2026.

This page will be revised when one of the following occurs:

• lawful access to the licensed ISO 10993-3:2026 final text permits a controlled clause-level review;
• FDA adds or changes a recognition decision for the 2026 edition;
• the European Commission cites the edition in an applicable harmonised-standards decision;
• BIS adopts the edition or CDSCO publishes a relevant standards or transition notice; or
• an official correction, amendment or interpretation materially changes the public assessment.

Keeping one canonical page prevents older transition notes from competing with later status. The publication facts, regulator status and implementation depth will be updated here rather than split across multiple versions.

Frequently Asked Questions

Limits of This Assessment

This article is educational. It does not reproduce ISO text, provide a device-specific endpoint or test decision, determine compliance, or guarantee regulator acceptance. Standards and regulator positions change. Verify the current controlled sources for the device, jurisdiction and submission date.